Back

Twelve versus 30 month dual antiplatelet therapy after percutaneous coronary intervention using national health insurance review & assessment (HIRA) database

29 August 2016 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 4 - Impact of stent design on post PCI outcomes PCI: long-term outcome ESC Premium Access ESC Congress 2016

About the speaker

Photo
Associate Professor Victor L Serebruany

Johns Hopkins University, Baltimore (United States of America)

18 More presentations in this session

Presentation thumbnail
Doctor M. Miura (Tokyo, JP)
Abstract
Presentation thumbnail
Doctor J. Ahn (Gumi, KR)
Presentation thumbnail
Doctor A. Levi (Petah Tikva, IL)
Abstract
Presentation thumbnail
Professor D. Kim (Busan, KR)
Abstract Slides
Presentation thumbnail
Doctor M. Ohya (Kurashiki, JP)
Abstract

Access the full session

Session thumbnail
Poster session 4 - Impact of stent design on post PCI outcomes

The Event

Event poster

ESC Congress 2016

29 August 2016 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention - a nationwide population-based study
30 August 2024
thumbnail
Congress Presentation
Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis
27 August 2022
thumbnail
Congress Session
Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more
28 August 2023
thumbnail
Congress Presentation
Perioperative risk and benefit of antiplatelet therapy in patients undergoing non-cardiac surgery within 1 year after percutaneous coronary intervention with second-generation drug-eluting stents.
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources